NHGRI Funds Next Step in Understanding Biological Roots of Common Diseases
News Jul 18, 2008
The National Human Genome Research Institute, one of the National Institutes of Health, announced grants expected to total about $31 million over the next four years for research aimed at gaining a better understanding of how specific genetic variants act to influence the risk of diabetes, heart disease, cancer and other common diseases.
Over the past two years, genome-wide association studies (GWAS) have allowed researchers to uncover more than 300 novel genetic variants associated with common diseases. However, the discovery of genetic variants through GWAS research represents just the first step in the challenging process of piecing together the complex biological picture of common diseases.
To help speed the process, NHGRI is supporting new research in existing large epidemiology studies, all with a rich range of measures of health and potential disease, and many with long-term follow-up.
The focus of the new research is on how genetic variants initially identified through GWAS research are related to a person's biological and physical characteristics, such as weight, cholesterol levels, blood sugar levels or bone density. Scientists will also examine how non-genetic factors, such as diet, medications and smoking, may interact with genetic factors or each other to influence health outcomes.
"By drawing on the combined strengths of genomics and epidemiology, this innovative program will create a much-needed research resource. The data it generates will save researchers around the world considerable time and energy, accelerating our ongoing efforts to translate genetic findings into new strategies for improving human health," said NHGRI Director Francis S. Collins, M.D., Ph.D.
The information generated by this program will help guide other genomic and epidemiologic studies by defining the potentially wide-ranging effects of genetic differences among people.
Additionally, it will lay the groundwork for laboratory experiments in cultured cells and other model systems to identify the precise biological mechanism affected by each genetic variant and how it interacts with other biological and environmental factors. Such information is vital to developing more individualized ways of preventing, diagnosing and treating common diseases.
"These investigators and cohorts were each chosen for their potential to provide important clues about how specific genetic variants might contribute to diseases like diabetes or cancer, which are a burden to public health," said Teri Manolio, M.D., Ph.D., director of the NHGRI Office of Population Genomics. "The investigators will collaborate to establish criteria and prioritize specific variants to test within their populations. Our plan is to investigate about 100 genetic variants in 10,000 participants each year for four years."
Below is a list of the NHGRI grantees, along with their estimated funding levels over four years, and the cohorts involved.
- Dana Crawford, Ph.D., Vanderbilt University, Nashville, Tenn. - $7 million
National Health and Nutrition Examination Survey (NHANES).
- Gerardo Heiss, M.D., Ph.D., University of North Carolina, Chapel Hill - $7 million
CALiCo Consortium: Atherosclerosis Risk In Communities (ARIC), Coronary Artery Risk In Young Adults (CARDIA), Cardiovascular Heart Study (CHS), Hispanic Community Health Study, the Strong Heart Cohort Study, the Strong Heart Family Study.
- Loîc Le Marchand, M.D., Ph.D., University of Hawaii Cancer Research Center, Honolulu - $6.7 million
- Charles L. Kooperberg, Ph.D., Fred Hutchinson Cancer Research Center, Seattle - $7.6 million
Women's Health Initiative.
A coordinating center will also be established to facilitate data access and analysis tools for the research community. The principal investigator of the coordinating center is Tara Matise, Ph.D., University of Rutgers Busch campus, Piscataway, N.J.
The center will receive approximately $3.1 million over four years. The coordinating center is being co-funded by the National Institute of Mental Health, which will contribute approximately $1.2 million over four years.
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE